CCRM Australia accelerates the commercialisation of Australian regenerative medicine therapies and related technologies. We do this through engagement and fostering local and international collaboration between industry, clinicians and academia; thereby nurturing local regenerative medicine companies for the international market.
Business of Regenerative Medicine Asia Pacific
CCRM Australia Prospectus
CCRM Australia 2018 Annual Report
The last 12 months have seen significant progress with CCRM Australia. With the endorsement of the 5-year strategic plan by the CCRM Australia Council and its subsequent approval by key stakeholders, CCRM Australia have been able to address many critical operational objectives and achieved several key milestones.
What is CCRM?
Australia’s leading regenerative medicine researchers have come together in a coordinated, collaborative fashion to support the creation of CCRM Australia.
CCRM Australia is a not for profit established to address bottlenecks in the translation and commercialisation of RM discoveries in Australia.
CCRM Australia is modelled on the highly successful CCRM in Canada and is legally separate to CCRM.
As a member of the Global CCRM network, CCRM Australia is a partner to a leading edge industry consortium. CCRM Australia is taking RM from bench to bedside by treating and potentially curing some of the most devastating and costly diseases in the world today.
What is Canada’s Centre for Commercialization of Regenerative Medicine (CCRM)?
Since its inception in 2011, CCRM has become globally recognised as a translation centre and has become a leading global commercial hub for regenerative medicine and cell therapy. In partnership with top research institutions in Canada and abroad, and with a consortium of global industry leaders, CCRM has established a track record of developing and commercialising innovative technologies that tackle significant bottlenecks in the industry.
Examples of this include:
- evaluation of novel biomaterials to enable cell product shipping,
- process optimisation on a cell therapy resulting in a 60% reduction in cost of goods,
- advancement of two novel drug screening platforms aimed at the direct measurement of contraction forces by contractile cells,
- co-development of image analysis software to enable analysis in a novel drug screening platform,
- development of novel cryopreservation approaches for specialised cells, and
- development of scalable expansion protocols for pluripotent stem cells.
CCRM has developed and implemented an efficient model for technology transfer that includes:
- in-licensing of technologies,
- value adding development either alone or in partnership with companies or academics,
- out-licensing of technologies/ processes to existing companies, and
- the bundling of technologies to create spin-out companies.
CCRM has approached ARMI at the Monash University Clayton Campus to establish an Australian ‘hub’ modelled along the CCRM operational model. This hub will be developed in parallel with other emerging hubs in Israel, Japan, Europe and Singapore.
The benefits of the introduction of the CCRM model to Australia include:
- immediate access to a demonstrated commercialisation model and sector specific expertise developed by CCRM to be utilised for the benefit of local regenerative medicine discoveries
- regenerative medicine product development, licensing and regulatory expertise
- membership of a large consortium that includes the major companies working in regenerative medicine
- access to a consortium of world-leading regenerative medicine companies providing business skills and leadership, funds for product development, and receptor capacity for technologies and products
- strong link to industry trends and needs through the industry consortium